Journal
EXPERT OPINION ON THERAPEUTIC TARGETS
Volume 14, Issue 12, Pages 1323-1332Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1517/14728222.2010.528395
Keywords
MAP kinase; MAP kinase phosphatase; metabolic disease; obesity
Categories
Funding
- NIH [R01, AR04625, DK57751, DK75776]
- Yale Liver Center Training [T32 DK07356]
Ask authors/readers for more resources
Importance of the field: Metabolic disease, which is associated with obesity and cardiovascular disease, is a worldwide epidemic. There continues to be a tremendous effort towards the development of therapies to curtail obesity and its associated pathophysiological sequelae. MAPKs have been implicated in metabolic disease suggesting that these enzymes, and those that regulate them, can potentially serve as therapeutic targets to combat this disease. The MAPK phosphatase-1 (MKP-1) mediates the dephosphorylation and inactivation of MAPKs in insulin-responsive tissues. Therefore, the actions of MKP-1 may play an important role in the maintenance of metabolic homeostasis. Areas covered in this review: The functional effects of MKP-1 in MAPK regulation with emphasis on its role in physiological and pathophysiological signaling functions that have been elucidated through the use of mouse genetics. What the reader will gain: The reader will learn that MAPK inactivation through the effects of MKP-1 is essential for the maintenance of metabolic homeostasis. We will convey the idea that MKP-1 acts as a critical signaling node in MAPK-mediated regulation of cell signaling and metabolism. Take home message: Pharmacological inactivation of MKP-1 may be of therapeutic value in the treatment of obesity and possibly other metabolic disorders.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available